Chalkis Health Industry Co., Ltd
000972.SZ · SHZ
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 589.29M | 154.68M | 31.70M | 26.09M | 0.03 |
| 2023 FY | 575.78M | 145.17M | 88.62M | 108.24M | 0.14 |
| 2024 FY | 308.15M | -223.29M | -222.88M | -230.78M | -0.30 |
| 2025 FY | 492.12M | -30.05M | -48.78M | -46.23M | -0.06 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 825.36M | 724.94M | 207.47M | 12.33M | 95.31M |
| 2023 FY | 1.22B | 1.01B | 110.65M | 418.21M | 203.54M |
| 2024 FY | 1.74B | 1.76B | 159.98M | 618.77M | -27.37M |
| 2025 FY | 1.22B | 1.19B | 312.66M | 630.91M | 26.12M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 197.75M | -14.09M | 183.66M | -12.91M | 155.16M |
| 2023 FY | -182.23M | -214.93M | -397.17M | -16.47M | -76.69M |
| 2024 FY | -97.60M | -35.64M | -133.24M | -26.53M | 50.81M |
| 2025 FY | 246.69M | -57.05M | 189.64M | -22.85M | 148.11M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2023 FY | 2.74B | 3.05B | — | — | — |
| 2024 FY | 2.16B | 2.62B | — | — | — |
| 2025 FY | 3.03B | 3.35B | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q2 | 166.24M | -23.12M | -68.80M | -67.45M | -0.09 |
| 2025 Q3 | 109.24M | -15.66M | -71.21M | -69.38M | -0.09 |
| 2025 Q4 | 137.94M | -5.50M | 182.21M | 97.86M | 0.13 |
| 2026 Q1 | 54.82M | 904.41K | -11.85M | -19.63M | -0.03 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q2 | 1.38B | 1.47B | 66.42M | 675.19M | -102.07M |
| 2025 Q3 | 1.25B | 1.42B | 109.09M | 731.93M | -171.46M |
| 2025 Q4 | 1.22B | 1.19B | 312.66M | 630.91M | 26.12M |
| 2026 Q1 | 1.16B | 1.16B | 281.76M | 680.20M | 6.49M |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q2 | 63.13M | -12.10M | 51.03M | -9.11M | -32.12M |
| 2025 Q3 | 71.13M | -9.19M | 61.94M | — | 42.66M |
| 2025 Q4 | 284.06M | -32.08M | 251.98M | -908.46K | 203.57M |
| 2026 Q1 | -2.92M | -6.51M | -9.43M | -566.48K | -30.90M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q2 | 2.74B | 3.35B | — | — | — |
| 2025 Q3 | 2.80B | 3.43B | — | — | — |
| 2025 Q4 | 3.03B | 3.35B | — | — | — |
| 2026 Q1 | 3.02B | 3.42B | — | — | — |